High-Throughput Screening and Rapid Inhibitor Triage Using an Infectious Chimeric Hepatitis C Virus
Michael Wichroski(Bristol-Myers Squibb (Germany)), Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Michele Agler(Franklin University), Monique Anthony(Bristol-Myers Squibb (United States)), John E. Leet(Franklin University), Samuel W. Gerritz(College of Wooster), Mark I. Cockett(Bristol-Myers Squibb (United States)), Brett R. Beno(Franklin University), Charles E. Mazzucco(Bristol-Myers Squibb (United States)), Ronald E. Rose(Bristol-Myers Squibb (United States)), Betsy J. Eggers(Bristol-Myers Squibb (United States)), Carl J. Baldick(Bristol-Myers Squibb (United States)), Kevin A. Pokornowski(Bristol-Myers Squibb (United States)), Lauren E. Barber(Franklin University), Jie Fang(Sun Yat-sen University), Craig J. Dowling(Bristol-Myers Squibb (United States))
Cited by 10
Related Papers
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239